CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.51
-0.68 (-5.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.19
Open12.17
Bid0.00 x 4000
Ask0.00 x 800
Day's Range11.40 - 12.17
52 Week Range8.32 - 20.66
Volume583,906
Avg. Volume783,762
Market Cap782.968M
Beta (3Y Monthly)3.29
PE Ratio (TTM)N/A
EPS (TTM)-3.23
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Coherus BioSciences, Inc. (NASDAQ:CHRS) Is Expected To Breakeven
    Simply Wall St.2 days ago

    Coherus BioSciences, Inc. (NASDAQ:CHRS) Is Expected To Breakeven

    Coherus BioSciences, Inc.'s (NASDAQ:CHRS): Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The US$590m market-cap posted a loss in its most recent financial year of Read More...

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    # Coherus BioSciences Inc ### NASDAQ NMS:CHRS View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for CHRS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $729 million over the last one-month into ETFs that hold CHRS are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire3 days ago

    Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Jan. 14, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 10, 2019, the compensation committee of the company’s.

  • GlobeNewswire10 days ago

    Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners

    Coherus BioSciences, Inc. (CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners. “We are pleased to have the renewed support of HealthCare Royalty Partners,” said Denny Lanfear, President and CEO of Coherus. “This investment reflects our continued confidence in the Coherus leadership team, as well as their ability to execute on their commercial plan,” said Clarke Futch, Managing Partner and Chairman of the Investment Committee of Healthcare Royalty Partners.

  • GlobeNewswire15 days ago

    Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference   

    REDWOOD CITY, Calif., Jan. 02, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37th annual J.P. Morgan healthcare.

  • See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
    Markit26 days ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents27 days ago

    Edited Transcript of CHRS earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Coherus BioSciences Inc Earnings Call

  • Markit28 days ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    # Coherus BioSciences Inc ### NASDAQ NMS:CHRS View full report here! ## Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Neutral Short interest is moderate for CHRS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold CHRS had net inflows of $259 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire29 days ago

    Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Dec. 19, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective December 18, 2018, the compensation committee of the company’s.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CHRS earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Coherus BioSciences Inc Earnings Call

  • Should You Buy Coherus Biosciences Inc (CHRS)?
    Insider Monkeylast month

    Should You Buy Coherus Biosciences Inc (CHRS)?

    Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]

  • See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    Coherus BioSciences Inc NASDAQ NMS:CHRS

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Coherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS

    REDWOOD CITY, Calif., Nov. 30, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the company has executed a 340B prime vendor program contract agreement.

  • Coherus BioSciences (CHRS): Moving Average Crossover Alert
    Zacks2 months ago

    Coherus BioSciences (CHRS): Moving Average Crossover Alert

    Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • GlobeNewswire2 months ago

    Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Nov. 27, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective November 14, 2018, the compensation committee of the company’s.

  • See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on November 8. Index (PMI) data, output in the Healthcare sector is rising.

  • Is Coherus BioSciences Inc’s (NASDAQ:CHRS) CEO Paid Enough Relative To Peers?
    Simply Wall St.2 months ago

    Is Coherus BioSciences Inc’s (NASDAQ:CHRS) CEO Paid Enough Relative To Peers?

    Denny Lanfear became the CEO of Coherus BioSciences Inc (NASDAQ:CHRS) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    Coherus BioSciences Inc NASDAQ NMS:CHRS

  • GlobeNewswire2 months ago

    Coherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference

    REDWOOD CITY, Calif., Nov. 12, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse.

  • Reuters2 months ago

    Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

    Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.

  • Associated Press2 months ago

    Coherus BioSciences: 3Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of 87 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • GlobeNewswire2 months ago

    Coherus BioSciences Reports Corporate Highlights and Third Quarter 2018 Financial Results

    REDWOOD CITY, Calif., Nov. 08, 2018 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended.

  • See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire2 months ago

    U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)

    REDWOOD CITY, Calif., Nov. 02, 2018 -- Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved UDENYCA™.